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Kenneth A. Kesler, MD,a Zane T. Hammoud, MD,a Paul R. Helft, MD,b Karen M. Rieger, MD,a Michael B. Pritz, MD, PhD,cand John W. Brown, MD,a Indianapolis, IndLocally advanced esophageal cancer remains a diseasewith a low long-term cure rate, despite combined mo-dality therapy, because of the frequent presence ofoccult metastatic disease. Metastatic disease to the cen-
tral nervous system (CNS) is unusual, with a reported incidence of
between 0.4% and 5.1%.1 Patients with esophageal cancer who do
present with CNS metastases after initial treatment represent a
clinical dilemma. Although several treatment strategies using ra-
diotherapy, surgical intervention, or both for CNS metastases exist,
a poor prognosis is anticipated. We report long-term survival in a
patient treated for a locally advanced adenocarcinoma of the
esophagus and subsequently for a CNS metastasis.
Clinical Summary
The patient presented in June 1999 as a 53-year-old healthy white
male with dysphagia and a 27-pound weight loss. Endoscopy
identified a mass in the distal esophagus from 35 to 39 cm. A
biopsy was positive for poorly differentiated adenocarcinoma. No
evidence of metastatic disease by means of computed tomographic
(CT) scans of the chest and abdomen was found. Transesophageal
ultrasonography demonstrated a transmural neoplasm with a cyto-
logically positive celiac lymph node equating to stage IVa disease.
He was treated with 4 cycles of cisplatin, 5-fluorouracil, leucov-
orin, and concurrent radiation (5040 cGy in 28 fractions), which he
tolerated well. Repeat CT scans revealed distal esophageal thick-
ening without interval development of metastatic disease. Six
weeks after completion of chemoradiation, esophagogastrectomy
with en bloc “2-field” (celiac-mediastinal) lymphadenectomy was
performed through an Ivor Lewis approach. He was discharged in
good condition on the 10th postoperative day. Final pathology
demonstrated extensive ulceration of the distal esophagus without
evidence of residual neoplasm. Of 17 lymph nodes harvested from
the surgical specimen, one had pathologic evidence of necrotic
(nonviable) neoplasm, whereas the remainder were found to be
free of previous or active disease.
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The Journal of ThoraciSix months after esophagogastrectomy, an acute mild right
hemiparesis developed. Magnetic resonance imaging revealed a
single 3-cm enhancing mass in the left posterior frontal lobe with
surrounding edema (Figure 1, A and B). No other evidence of
recurrent disease on repeat CT scans, as well as endoscopy, was
found. The patient underwent craniotomy and complete excision.
Pathologic analysis confirmed a poorly differentiated adenocarci-
noma with marked necrosis consistent with a metastasis from the
primary esophageal neoplasm. He was discharged on the third
postoperative day without residual hemiparesis and received adju-
vant whole-brain radiation therapy beginning 3 weeks postopera-
tively (3375 cGy in 15 fractions). He has been carefully followed
with CT imaging and endoscopy on a routine basis. The patient
remains alive and well 6 years after esophagogastrectomy and 5.5
years after excision of the brain metastasis.
Discussion
Several treatment options exist for symptomatic brain metastases,
including whole-brain radiation, stereotactic radiation, and surgi-
cal intervention, which can be used alone or in combination.
Because prospective clinical trials are lacking, treatment selection
has been individualized on the basis of a number of variables,
including tumor location, tumor size, number of CNS metastases,
functional status, presence or absence of extracranial disease, and
institutional biases. Two recent retrospective studies of patients
with esophageal cancer with CNS metastases and mainly adeno-
carcinoma histology have been published. Weinberg and col-
leagues1 reviewed 27 patients from M.D. Anderson Hospital. The
median survival after the diagnosis of a CNS metastasis was 3.8
months. The longest survival was 9.6 months, which occurred in
one of the 4 patients who were treated with surgical intervention
and whole-brain radiation. Khuntia and associoates2 reported the
Cleveland Clinic experience with 27 patients, of whom 7 were
selected to undergo surgical intervention. In 5 of these patients,
surgical intervention was used in combination with whole-brain
radiation. The median survival was 3.6 months; however, 1 patient
survived for 48 months. Survival in both series appeared to be
improved with aggressive therapy, which included surgical inter-
vention, offered only to a select subset of patients.
Mao and coworkers3 reported a patient with a clinical stage II
adenocarcinoma of the esophagus treated with neoadjuvant che-
moradiation therapy followed by esophagogastrectomy. An iso-
lated CNS metastasis was treated with surgical intervention and
whole-brain radiation 18 months later. The patient had survived
more than 7 years at the time of the report. In a recent study from
our institution,4 a cohort of 176 patients surgically treated for
locally advanced adenocarcinoma was analyzed. Further analysis
of these data identified 4 (2.3%) patients who were subsequently
found to have CNS metastases. Three of these patients had re-
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the other underwent surgical intervention without chemoradiation
therapy. Two patients, including the patient in this report, demon-
strated an isolated CNS metastasis without evidence of other
disease. The other 3 patients were treated with radiation and died
after an average of 6 months. We believe our patient and the
patient previously reported demonstrated several variables that
might be predictive of prolonged survival, including a good per-
formance status, complete or near-complete pathologic response to
neoadjuvant chemoradiation, and isolated lesions amenable to
complete surgical excision.
Conclusion
Reported outcomes of patients with esophageal cancer with CNS
metastases have been dismal. Previous retrospective series, how-
ever, have been small and included a relatively heterogeneous
group of patients with respect to several prognostic variables, and
most patients have received nonsurgical treatment. CNS metasta-
ses after treatment of esophageal cancer will likely become more
frequent because the incidence of adenocarcinoma is increasing
and systemic (versus local) recurrence is becoming more common
with the escalating use of neoadjuvant chemoradiation therapy. We
believe that carefully selected patients have the potential to expe-
rience long-term survival and therefore should be treated aggres-
sively.
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